RxDoctor Payments Data

Timothy Greco

Bala Cynwyd, PANPI 1952442378

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $137,329 of the $178,591 with a category attached, or 76.9%. AbbVie accounts for 74.3% of it on its own, with 2 other manufacturers making up the rest. Reporting peaked in 2019 at $55,648 and has fallen 84.8% since, to $8,471 in 2025.

$178,591in general payments, 2019–2025

Across 189 payments — averaging $944.92 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$133K
  • Galderma Laboratories, L.p.$45K
  • Merz North America, Inc.$521

What the payments were for

  • Consulting fees$16,4009%
  • Speaking & faculty fees$137,32977%
  • Travel & lodging$21,46812%
  • Food & beverage$3,3942%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
AbbVie(2 entities)143$132,724
Galderma Laboratories, L.p.37$45,345
Merz North America, Inc.9$521

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Tobramycin-DexamethasoneTobramycin/Dexamethasone12$520
ValacyclovirValacyclovir Hcl26$487
Mupirocin46$299
Ketorolac Tromethamine13$167
Cephalexin14$90
Oxycodone-AcetaminophenOxycodone Hcl/Acetaminophen17$42
Ondansetron OdtOndansetron22$33
Zolpidem Tartrate12$23
Diazepam14$17

Paid to pharmacies, not to this prescriber.

Where these figures come from

Is this you, or does something look wrong? →